The goal of this study is to identify changes in cells that are related to the treatment with Cat-PAD (ToleroMune Cat).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in the area under the curve (AUC) from 0 to 6 hour for total nasal symptom score (TNSS).
Timeframe: Following nasal allergen challenge , one year after initiation of peptide immunotherapy.